FDA Compounding Rules 2026: Is Compounded Semaglutide Still Legal?
FDA compounding exemption May 2026: 503A patient-specific compounding remains legal post-shortage. Section 503A framework for compounded GLP-1 explained.
More on GLP-1 Access & Regulations
Compounded Semaglutide vs Wegovy
Are they actually the same medication?
GLP-1 Shortage Update 2026
Current supply status of all GLP-1 medications.
Online Compounding Service Safety
How to evaluate the safety of online GLP-1 providers.
Trimi Compounded Quality & Compliance
How Trimi ensures quality in its compounded medications.
Last Updated: April 2026
FDA compounding regulations for GLP-1 medications have been in flux since early 2025. This article reflects the current legal landscape as understood in April 2026. Regulations may continue to evolve — check with your provider for the most current status.
The Regulatory Landscape in Plain English
The compounding industry for GLP-1 medications has been operating in a complex and evolving legal environment since late 2024. The core issue: the FDA's Drug Shortage List was the primary legal mechanism that allowed large-scale compounding of semaglutide and tirzepatide by 503B outsourcing facilities. When both drugs were removed from the shortage list (tirzepatide in late 2024, semaglutide in early 2025), the FDA took the position that 503B facilities must cease compounding these drugs.
However, the story didn't end there. Several compounding industry groups and individual pharmacies challenged the FDA's authority in federal court. Multiple court rulings created injunctions and legal uncertainty that prevented the FDA from enforcing a complete shutdown. In parallel, the 503A pathway (patient-specific compounding by state-licensed pharmacies) continued largely unaffected, as it operates under a different legal framework that doesn't depend on shortage list status.
The result in April 2026: compounded semaglutide and tirzepatide remain available through both 503A pharmacies and many 503B outsourcing facilities, though the latter face ongoing regulatory pressure. Reputable telehealth providers have adapted their pharmacy networks to operate within current legal frameworks. For related context, see our article on the GLP-1 shortage update for 2026.
The Legal Framework: 503A vs 503B Compounding
503A Compounding (Traditional)
- Patient-specific prescriptions only
- Regulated primarily by state pharmacy boards
- Not FDA-inspected (state oversight)
- Does NOT require shortage list status
- Legal in 2026 for semaglutide/tirzepatide with a valid prescription
- Quality standards vary widely by pharmacy
503B Outsourcing Facilities
- Registered with and inspected by FDA
- Must follow current Good Manufacturing Practices (cGMP)
- Highest quality standard for compounding
- Can produce larger batches
- Status for semaglutide compounding contested post-shortage list
- Check current regulatory status with your provider
Timeline of Key Regulatory Events
How to Evaluate a Compounding Provider's Legitimacy
Given the regulatory complexity, it's more important than ever to understand what separates legitimate, compliant compounding providers from lower-quality or non-compliant operators. Key questions to ask:
Which pharmacy produces the medication?
A legitimate provider will disclose their pharmacy network. Look up 503B facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.
What form of semaglutide is used?
Must be semaglutide free base or sodium — NOT semaglutide acetate. Ask explicitly if the documentation is not clear.
Is there batch testing documentation?
Certificates of Analysis (CoA) for sterility, endotoxin testing, and potency should be available. If a provider can't or won't provide CoAs, look elsewhere.
Is there licensed physician oversight?
All prescriptions require a licensed physician. Telehealth programs should include ongoing medical supervision, not just a one-time prescription.
Is PCAB accreditation held?
The Pharmacy Compounding Accreditation Board (PCAB) provides independent quality verification. PCAB-accredited pharmacies meet high voluntary standards.
Trimi partners exclusively with pharmacies that meet rigorous quality standards. Read about Trimi's quality and compliance standards.
What This Means for Patients Starting or Continuing Treatment
For patients currently on compounded semaglutide or tirzepatide through a compliant telehealth provider: your treatment is not in immediate jeopardy. Compliant providers have adapted their operations to work within the current legal framework and continue to have legal pathways to provide compounded GLP-1 medications.
For patients considering starting: compounded GLP-1 medications remain a legal and cost-effective option through compliant providers. The key is choosing a provider that operates within the appropriate regulatory framework. See our cheapest legal GLP-1 online cornerstone covering Hims, Ro, Found, Mochi, Henry Meds, LillyDirect with 503A pharmacy compliance citations, and our guide on evaluating online compounding services for a comprehensive checklist.
Trimi's approach has always prioritized compliance and quality over cost minimization. Our pharmacy relationships and medical oversight model are designed to remain viable regardless of further regulatory evolution. Get started with a medical assessment at our how it works page.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Yes. While semaglutide was removed from the FDA drug shortage list in early 2025 (eliminating shortage-based compounding), compounding pharmacies can still legally produce semaglutide under Section 503A (patient-specific prescriptions) and Section 503B (outsourcing facilities). Multiple court rulings in 2025 also challenged the FDA's authority to completely ban 503B compounding after shortage list removal.
What is the difference between 503A and 503B compounding?
503A pharmacies compound patient-specific prescriptions under state pharmacy board oversight. 503B outsourcing facilities are registered with the FDA, subject to FDA inspections, must follow current Good Manufacturing Practices (cGMP), and can produce larger batches without patient-specific prescriptions. 503B facilities offer stronger quality assurance.
What happened when semaglutide was removed from the FDA shortage list?
When semaglutide was removed from the FDA's Drug Shortage List in early 2025, the FDA issued guidance stating that 503B outsourcing facilities could no longer compound semaglutide based on shortage status alone. However, 503A compounding for individual patients and 503B compounding under other qualifying conditions remained legal, and federal courts have since created additional regulatory uncertainty that has allowed many providers to continue operations.
What is semaglutide acetate and why should I avoid it?
Semaglutide acetate is a chemically distinct salt form of semaglutide that is NOT used in any FDA-approved drug (Ozempic/Wegovy use semaglutide sodium or free base). Semaglutide acetate has not been validated in human clinical trials and should not be used. Reputable compounding pharmacies use only validated forms of semaglutide.
How can I verify my compounding pharmacy is legitimate?
Check for: (1) 503B outsourcing facility registration on the FDA website (fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities), (2) PCAB (Pharmacy Compounding Accreditation Board) accreditation, (3) State pharmacy board licensing, (4) Certificates of Analysis (CoA) for each batch showing sterility and potency testing, (5) A licensed physician providing medical oversight of prescriptions.
Sources & References
- FDA. "Drug Compounding." fda.gov/drugs/guidance-compliance-regulatory-information/compounding. 2024.
- FDA. "Registered Human Drug Outsourcing Facilities under Section 503B." fda.gov. 2024.
- Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. US Code.
- FDA. "Guidance for Industry: Compounding Under Sections 503A and 503B." 2023.
- Alliance for Pharmacy Compounding. "503A vs 503B: Key Differences." a4pc.org. 2024.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.